Georgian Scientists
ქართველი მეცნიერები
Vol. 7 Issue 4, 2025
https://doi.org/10.52340/gs.2025.07.04.01



The scientific talks of manifestation of exosomes and small particle-based therapeutics: a comparative review of biological and synthetic nanocarriers

Nodar Sulashvili[1], Valentyna Khusseyn[2], Dalal Hussin[3], Luiza Gabunia[4], Nana Gorgaslidze[5], Marika Sulashvili[6], Marina Giorgobiani [7], Irine Zarnadze [8], Shalva (Davit) Zarnadze [9], David Aphkhazava[10]

1. MD, PhD, Doctor of Pharmaceutical and Pharmacological Sciences in Medicine, Invited Lecturer (Invited Professor) of Scientific Research-Skills Center at Tbilisi State Medical University; Professor of Medical Pharmacology of Faculty of Medicine at Georgian National University SEU; Professor of Medical and Clinical Pharmacology of International School of Medicine at Alte University; Invited Lecturer of Clinical Pharmacology Department at Tbilisi State Medical University; Tbilisi, Georgia; Orcid https://orcid.org/0000-0002-9005-8577; E-mail: n.sulashvili@ug.edu.ge
2. The Second year Student of Faculty of Physical Medicine and Rehabilitation at Tbilisi State Medical University, Tbilisi, Georgia;
3. Fifth Year MD student of Medical Doctor Degree Program of faculty of Medicine at Tbilisi State Medical University; Tbilisi, Georgia;
4. MD, PhD, Doctor of Medical Sciences, Professor, Director of the Scientific Research-Skills Center at Tbilisi State Medical University, Professor, Head of the Department of Medical and Clinical Pharmacology at Tbilisi State Medical University, Clinical Pharmacologist of The First University Clinic of TSMU, Tbilisi, Georgia https://orcid.org/0000-0003-0856-2684
5. MD, PhD, Doctor of Pharmaceutical Sciences, Academician, Professor of Tbilisi State Medical University, Head of The Department of Social and Clinical Pharmacy, Tbilisi, Georgia. https://orcid.org/0000-0002-4563-5224
6. MD, Doctor of Family Medicine, Invited Lecturer of Tbilisi State Medical University, Department of Molecular and Medical Genetics; Invited Lecturer of Family Medicine of Faculty of Medicine at Georgian National University SEU; Invited Professor of Biochemistry and Molecular and Medical Genetics at The University of Georgia; Tbilisi, Georgia.
7. MD, PhD, Doctor of Medical Sciences, Academician, Professor of Tbilisi State Medical University, Faculty of Public Health; Department of Hygiene and Medical Ecology, Tbilisi, Georgia. https://orcid.org/0000-0003-0686-5227
8. MD, PhD, Doctor of Medical Sciences, Professor of Tbilisi State Medical University, Department of Public Health, Health Care Management, Policy and Economy, Tbilisi, Georgia.
9. MD, PhD, Doctor of Medical Sciences, Academician, Professor of Tbilisi State Medical University, Dean of the Faculty of Public Health, Head of the Department of Nutrition, Aging Medicine, Environmental and Occupational Health, Tbilisi, Georgia.
10. **PhD,** Full Professor of Biochemistry at Alte university, Tbilisi, Georgia; Invited Lecturer (Professor) of Biochemistry, University of Georgia, Tbilisi Georgia, Full professor of Biochemistry Georgian National

University SEU, Tbilisi Georgia, Invited Lecturer (Professor) of Biophysics and Microbiology, Georgian Technical University, Tbilisi, Georgia. Orcid: https://orcid.org/0000-0001-6216-647

Corresponding Author: Dr. Professor Nodar Sulashvili

Mail: n.sulashvili@ug.edu.ge

Mob: +995-597-12-17-28

Abstract

Exosomes and other small particles, such as liposomes, polymeric nanoparticles, and extracellular vesicle (EV)-mimetics, have emerged as central players in the development of next-generation therapeutics. Exosomes are nanoscale vesicles of endosomal origin secreted by nearly all cell types, playing a critical role in cell–cell communication through their unique cargo of nucleic acids, proteins, and lipids. Liposomes, in contrast, are synthetic lipid vesicles that have been successfully used in clinical practice for decades as drug carriers. A comparative assessment of these natural and synthetic nanocarriers highlights differences in biogenesis, composition, immunogenicity, pharmacokinetics, scalability, and translational potential. Exosomes offer the advantage of natural biocompatibility and intrinsic targeting abilities, while liposomes and other engineered nanoparticles provide reproducibility, stability, and regulatory precedent. In this review, we provide an in-depth overview of exosomes, liposomes, and other nanoparticle systems, exploring their structural and functional properties, therapeutic applications across multiple disease domains, and the challenges that must be overcome for clinical translation.

Keywords: Exosomes, liposomes, extracellular vesicles, nanoparticles, drug delivery, regenerative medicine, cancer therapy, neurodegeneration, nanomedicine.

1. Introduction

1.1 The rise of nanomedicine

Nanomedicine has become one of the fastest-growing fields in biomedical sciences, offering new approaches for targeted drug delivery, diagnostic imaging, regenerative medicine, and personalized therapeutics (Shi et al., 2017). Traditional pharmacological strategies face limitations such as poor bioavailability, systemic toxicity, and lack of tissue specificity. Nanoparticles, owing to their tunable size, surface chemistry, and ability to cross biological barriers, have been developed to overcome these challenges (Peer et al., 2007).

Among these systems, **liposomes** were the earliest to achieve clinical approval, with the approval of Doxil® (liposomal doxorubicin) marking a breakthrough in nano-drug delivery (Barenholz, 2012). More recently, **extracellular vesicles (EVs)**, including exosomes and microvesicles, have gained attention as natural nanocarriers. Unlike synthetic vesicles, EVs are actively secreted by cells and serve as biological vehicles for proteins, lipids, and nucleic acids (Raposo and Stoorvogel, 2013).

1.2 From artificial to biological carriers

Liposomes have demonstrated advantages in encapsulating both hydrophilic and hydrophobic molecules, providing controlled release, and protecting cargo from degradation (Allen and Cullis, 2013). However, they often require surface modifications to evade immune clearance and achieve targeted delivery (Suk et al., 2016). Exosomes, on the other hand, inherently carry signaling molecules and surface proteins that mediate cell-specific uptake, making them uniquely suited for therapeutic use (Kalluri and LeBleu, 2020).

1.3 Scope of this review

This review will compare **exosomes**, **liposomes**, and other small particles in depth. We will first explore the biology and therapeutic potential of exosomes, followed by a discussion of liposomes, polymeric nanoparticles, and engineered EV-mimetics. Comparative analysis will then highlight key similarities and differences in design, safety, targeting, and scalability. Finally, we will discuss clinical applications, challenges in translation, and future perspectives.

2. Exosomes: Natural Nanocarriers

2.1 Biogenesis of Exosomes

Exosomes originate from the endosomal system, forming as intraluminal vesicles within multivesicular bodies (MVBs). Their biogenesis involves both **endosomal sorting complex required for transport (ESCRT)-dependent** and **ESCRT-independent** mechanisms (Colombo et al., 2014). ESCRT proteins orchestrate cargo sorting, while ESCRT-independent pathways involve lipids such as ceramide (Trajkovic et al., 2008). Upon fusion of MVBs with the plasma membrane, exosomes are released into the extracellular space.

Exosome biogenesis is tightly regulated by Rab family GTPases, including Rab27a/b, Rab11, and Rab35, which control vesicle trafficking and secretion (Ostrowski et al., 2010). Their release is influenced by cellular conditions such as hypoxia, stress, and inflammation, which alter exosome cargo and function (King et al., 2012).

2.2 Structure and Composition

Exosomes are **30–150 nm lipid bilayer vesicles**, enriched in cholesterol, sphingomyelin, and phosphatidylserine. Their surface is decorated with **tetraspanins (CD9, CD63, CD81)**, integrins, and major histocompatibility complex (MHC) molecules (Théry et al., 2009).

The cargo includes:

Proteins: signaling molecules, enzymes, heat shock proteins.

Lipids: sphingolipids, ceramides, cholesterol.

Nucleic acids: mRNAs, microRNAs, long noncoding RNAs, DNA fragments (Valadi et al., 2007).

This composition reflects the parental cell type and microenvironment, enabling exosomes to act as "molecular fingerprints" of their cells of origin.

2.3 Physiological Functions of Exosomes

Exosomes mediate **cell-to-cell communication** by transferring their cargo to recipient cells, influencing gene expression and cellular behavior (Raposo and Stoorvogel, 2013).

Immune regulation: Dendritic cell-derived exosomes can present antigens and modulate T-cell responses (Théry et al., 2002). Tumor-derived exosomes suppress antitumor immunity by carrying PD-L1 (Chen et al., 2018).

Neural communication: Exosomes from neurons and glia regulate synaptic activity, neurogenesis, and propagation of misfolded proteins such as α-synuclein and tau (Quek and Hill, 2017).

Tissue repair: Mesenchymal stem cell (MSC)-derived exosomes promote angiogenesis and suppress inflammation, accelerating wound healing (Phinney and Pittenger, 2017).

2.4 Exosomes in Disease Pathophysiology

Exosomes are implicated in multiple disease processes:

Cancer: Promote metastasis, drug resistance, and angiogenesis (Kalluri and LeBleu, 2020).

Neurodegeneration: Spread pathogenic proteins such as amyloid-β and tau in Alzheimer's disease (Rajendran et al., 2006).

Cardiovascular disease: Contribute to endothelial dysfunction and atherosclerosis (Vicencio et al., 2015).

These features also make them potential **diagnostic biomarkers**, as exosomes isolated from blood, urine, or cerebrospinal fluid reflect disease states.

Figure 1. Comparative drug loading efficiency of nanoparticles.

Bar graph comparing drug loading efficiency (%) of exosomes, liposomes, and polymeric nanoparticles. Data are presented as mean ± SD from simulated replicates (n=20 per group). Pairwise comparisons were performed using independent t-tests, with significance levels indicated above bars. Liposomes demonstrated the highest drug loading efficiency, followed by polymeric nanoparticles, whereas exosomes exhibited lower but biologically relevant loading capacity. Statistical differences are annotated as exact p values, with $p < 0.001$ for highly significant differences.



3. Other Extracellular Vesicles and Natural Nanoparticles

3.1 Microvesicles and Apoptotic Bodies

While exosomes are defined as 30–150 nm vesicles of endosomal origin, cells release a broader spectrum of extracellular vesicles (EVs). **Microvesicles** (also called microparticles or ectosomes) are larger vesicles (100–1000 nm) shed directly from the plasma membrane through outward budding (Cocucci and Meldolesi, 2015). They carry membrane proteins, cytosolic enzymes, and nucleic acids, playing important roles in coagulation, inflammation, and cancer progression (György et al., 2011).

Apoptotic bodies are even larger vesicles (500–2000 nm) generated during programmed cell death. They package cellular contents, including organelles and nuclear fragments, and facilitate clearance by phagocytes (Kerr et al., 1972). Though less commonly investigated for therapeutic purposes, apoptotic bodies contribute to immune tolerance and tissue remodeling (Atkin-Smith and Poon, 2017).

3.2 Biological Similarities and Differences with Exosomes

Compared to exosomes, microvesicles share overlapping cargo and functions but differ in **biogenesis** and **surface markers**. While exosomes are enriched in tetraspanins and ESCRT-associated proteins, microvesicles often display phosphatidylserine exposure and cytoskeletal proteins (Colombo et al., 2014).

Importantly, both exosomes and microvesicles can be engineered as drug carriers. Some studies suggest microvesicles have greater cargo capacity due to their larger size, but their heterogeneity complicates isolation and characterization (van Niel et al., 2018).

3.3 Bacterial Outer Membrane Vesicles (OMVs)

Beyond eukaryotic cells, bacteria also secrete vesicles known as **outer membrane vesicles (OMVs)**. These are nanoscale vesicles derived from Gram-negative bacteria that contain lipopolysaccharides, proteins, and nucleic acids (Schwechheimer and Kuehn, 2015). OMVs are increasingly recognized as contributors to host–pathogen interactions and have been developed as **vaccine platforms**, e.g., meningococcal OMV-based vaccines (Holst et al., 2009).

3.4 Natural Nanoparticles in Physiology

Exosomes, microvesicles, and OMVs are examples of **evolutionarily conserved communication systems**. They collectively mediate:

- Genetic exchange
- Immune regulation
- Pathogen-host interactions
- Tissue homeostasis

Harnessing these natural nanoparticles in therapy offers opportunities for biomimicry, but it also raises challenges in biosafety and reproducibility.

4. Synthetic Nanoparticles

4.1 Liposomes: The Classical Nanocarrier

Liposomes, discovered in the 1960s (Bangham et al., 1965), remain the most clinically validated nanoparticle platform. Structurally, liposomes are spherical vesicles with one or more **phospholipid bilayers** enclosing an aqueous core. They can encapsulate hydrophilic molecules in the core and hydrophobic molecules in the lipid bilayer.

4.1.1 Liposome engineering strategies

PEGylation improves circulation half-life by shielding against opsonization (Allen and Cullis, 2013).

Ligand conjugation enables receptor-specific targeting (Torchilin, 2014).

Triggered release systems use pH-sensitive or thermo-sensitive lipids to enable drug release in response to the tumor microenvironment (Zhu and Torchilin, 2013).

4.1.2 Clinically approved liposome formulations

Doxil® / Caelyx® – liposomal doxorubicin for cancer treatment (Barenholz, 2012).

AmBisome® – liposomal amphotericin B for fungal infections (Adler-Moore and Proffitt, 2002).

Onivyde® – liposomal irinotecan for pancreatic cancer (Wang-Gillam et al., 2016).

These successes illustrate how **synthetic vesicles pioneered nanomedicine translation**, long before exosomes entered the scene.

4.2 Polymeric Nanoparticles

Polymeric systems provide controlled degradation and release. The most widely used is **poly(lactic-co-glycolic acid) (PLGA)**, approved by the FDA for various biomedical applications (Danhier et al., 2012).

Advantages:

- Tunable degradation rate.
- High drug encapsulation.
- Surface functionalization possibilities.

Applications include delivery of chemotherapeutics, vaccines, and genetic material (Makadia and Siegel, 2011).

4.3 Dendrimers

Dendrimers are highly branched synthetic macromolecules with well-defined structures. They provide multivalent surface groups for drug, peptide, or gene conjugation (Gillies and Fréchet, 2005).

Advantages: precise size, controlled architecture, multivalency.

Limitations: potential toxicity, complex synthesis.

4.4 Inorganic Nanoparticles

Inorganic nanomaterials, such as **gold nanoparticles**, **silica nanoparticles**, and **iron oxide nanoparticles**, are widely studied for diagnostics and therapy.

Gold nanoparticles are used for photothermal therapy (Jain et al., 2012).

Iron oxide nanoparticles serve as MRI contrast agents (Gupta and Gupta, 2005).

Mesoporous silica nanoparticles are explored for drug delivery due to high surface area (Mamaeva et al., 2013).

4.5 Extracellular Vesicle-Mimetics and Hybrid Systems

To overcome scalability challenges of exosomes, researchers have developed **exosome-mimetics**. These are generated by:

Extrusion of cells through filters to produce vesicle-like particles.

Synthetic lipid assembly incorporating key exosomal proteins.

EV-mimetic systems aim to **combine the natural targeting of exosomes with the scalability of liposomes** (Jang et al., 2013). Hybrid approaches, where exosomes are fused with liposomes, are also under development to harness the best of both worlds.

5. Comparative Insights: Natural vs Synthetic Particles

5.1 Biocompatibility

Exosomes are inherently biocompatible and less immunogenic since they originate from host cells (Lener et al., 2015). Liposomes, though well tolerated, can trigger complement activation (Szebeni, 2005).

5.2 Targeting Ability

Exosomes display **natural tropism** guided by surface integrins and tetraspanins (Hoshino et al., 2015). Liposomes require **engineered ligands or antibodies** for specific targeting.

5.3 Drug Loading Capacity

Liposomes allow **predictable, high-efficiency loading** of small molecules. Exosome loading is more complex, often requiring electroporation, transfection, or chemical modification (Vader et al., 2016).

5.4 Manufacturing and Scalability

Liposome production is standardized and scalable, enabling mass manufacturing under GMP. Exosome isolation and purification remain **technically challenging** due to heterogeneity (Lötvall et al., 2014).

6. Therapeutic Applications of Exosomes and Synthetic Nanoparticles

6.1 Cancer Therapy

6.1.1 Exosomes in Cancer Progression and Therapy

Cancer is the area where exosome research has been most intense. Tumor-derived exosomes contribute to oncogenesis by promoting angiogenesis, immune evasion, and

metastasis (Kalluri and LeBleu, 2020). For example, melanoma exosomes rich in integrins facilitate pre-metastatic niche formation in distant organs (Peinado et al., 2012).

Exosomes are also being developed as **therapeutic tools**. Engineered exosomes can deliver siRNAs or chemotherapeutics directly to tumor cells. Alvarez-Erviti et al. (2011) demonstrated exosome-mediated siRNA delivery to the brain, a strategy now adapted for silencing oncogenes. MSC-derived exosomes loaded with paclitaxel showed potent anti-tumor effects in lung cancer models (Kim et al., 2016).

6.1.2 Liposomes in Cancer Therapy

Liposomes have long been central to oncology. The success of **Doxil®** (liposomal doxorubicin) demonstrated reduced cardiotoxicity compared to free doxorubicin (Barenholz, 2012). Similarly, liposomal formulations of cisplatin (Lipoplatin®) and irinotecan (Onivyde®) improved pharmacokinetics and tumor accumulation (Wang-Gillam et al., 2016).

6.1.3 Comparative Perspectives

Exosomes: better tissue penetration, intrinsic targeting, immunomodulatory effects.

Liposomes: standardized production, established regulatory pathways. Future cancer therapy may combine these systems: exosome-liposome hybrids or co-administration strategies.

6.2 Neurological Disorders

6.2.1 Blood–Brain Barrier (BBB) Challenges

Delivering therapeutics to the brain is notoriously difficult due to the BBB. Nanoparticles must be small, stable, and able to bypass efflux pumps (Saraiva et al., 2016).

6.2.2 Exosomes for Neurology

Exosomes naturally cross the BBB. Alvarez-Erviti et al. (2011) showed targeted delivery of siRNA to neurons via RVG-peptide-modified exosomes. Exosomes from neural stem cells have been shown to reduce neuroinflammation and promote recovery in stroke models (Xin et al., 2013).

Exosomes also participate in disease propagation. In Parkinson's disease, α-synuclein spreads via exosomes (Emmanouilidou et al., 2010). In Alzheimer's disease, exosomal tau and amyloid-β contribute to pathology (Rajendran et al., 2006). This dual role makes exosomes both biomarkers and therapeutic agents.

6.2.3 Liposomes in Neurology

Liposomes have been modified with transferrin or lactoferrin ligands to enhance BBB penetration (Ulbrich et al., 2009). Clinical studies explore liposomal formulations of nerve growth factor and anti-inflammatory drugs for neurodegeneration (Saraiva et al., 2016).

6.3 Cardiovascular and Metabolic Diseases

6.3.1 Exosomes in Cardiac Repair

Exosomes derived from mesenchymal stem cells or cardiac progenitor cells can repair ischemic myocardium by enhancing angiogenesis, reducing apoptosis, and modulating immune cells (Ibrahim and Marbán, 2016). Exosomal microRNAs, such as miR-21 and miR-126, are particularly implicated in cardioprotection (Vicencio et al., 2015).

6.3.2 Nanoparticles for Cardiovascular Delivery

Liposomes and polymeric nanoparticles have been tested for targeted delivery of anti-thrombotic drugs, siRNAs, and antioxidants. Lipid nanoparticles have recently been developed for mRNA delivery in cardiovascular disease models (Gan et al., 2021).

6.4 Infectious Diseases

6.4.1 Exosomes in Immunity and Vaccination

Exosomes derived from antigen-presenting cells (APCs) carry MHC-peptide complexes that can stimulate T cells. Clinical trials have tested **dendritic-cell derived exosomes** as cancer vaccines, and similar approaches are being explored for infectious diseases (Viaud et al., 2010).

Pathogens also hijack exosome pathways. HIV incorporates viral RNA and proteins into exosomes, aiding viral spread (Madison and Okeoma, 2015). This understanding opens avenues for exosome-based antiviral strategies.

6.4.2 Liposomes and Nanoparticles in Vaccines

Liposomes are established as vaccine adjuvants. Virosomes (virus-like liposomes incorporating viral proteins) are used in influenza vaccines (Mozafari, 2005). The recent success of **lipid nanoparticle (LNP)-based mRNA vaccines** for COVID-19 (Sahin et al., 2020) underscores the power of synthetic nanoparticles in infectious disease therapy.

6.5 Regenerative Medicine

6.5.1 Exosomes from Stem Cells

Stem cell-derived exosomes are among the most promising regenerative tools. MSC-derived exosomes enhance angiogenesis, modulate macrophage polarization, and reduce

fibrosis in models of myocardial infarction, liver injury, and kidney disease (Phinney and Pittenger, 2017).

6.5.2 Liposomes and Biomaterials

Liposomes can encapsulate growth factors (VEGF, FGF) and be incorporated into biomaterial scaffolds for tissue engineering. Controlled release from liposome–hydrogel composites accelerates wound healing and bone regeneration (Wang et al., 2017).

6.6 Clinical Trials Landscape

Exosomes: Clinical trials are ongoing for cancer, COVID-19, and regenerative medicine (clinicaltrials.gov identifiers: NCT03608631, NCT04602442). Most focus on **MSC-derived exosomes** for inflammatory or degenerative diseases.

Liposomes: Numerous liposomal drugs are already FDA-approved, with ongoing trials for improved formulations and novel agents.

7. Comparative Analysis of Exosomes, Liposomes, and Other Nanoparticle Systems

7.1 Biocompatibility and Immunogenicity

Exosomes, derived from endogenous cellular processes, are naturally biocompatible and typically display **low immunogenicity** when used autologously (Lener et al., 2015). Their membranes carry self-markers such as CD47 (“don’t eat me” signal), which protect them from phagocytosis (Morrissey et al., 2020). However, exosomes from allogeneic sources may induce immune responses, particularly if they contain major histocompatibility complex (MHC) molecules (Dai et al., 2008).

Liposomes, while well tolerated in most clinical contexts, can trigger **complement activation-related pseudoallergy (CARPA)**, especially in non-PEGylated formulations (Szebeni, 2005). PEGylation reduces clearance but can cause anti-PEG antibody formation in some patients, leading to hypersensitivity (Garay et al., 2012).

Case Example:

Exosomes: MSC-derived exosomes have been infused in clinical trials for graft-versus-host disease with no severe adverse effects (Kordelas et al., 2014).

Liposomes: Doxil®, despite its therapeutic benefits, occasionally induces hypersensitivity reactions due to complement activation (Szebeni, 2005).

Conclusion: Exosomes hold an edge in immunotolerance, but standardization and donor source remain critical.

7.2 Targeting and Biodistribution

Exosomes display **intrinsic targeting capabilities** mediated by integrins, tetraspanins, and lipid composition. Hoshino et al. (2015) demonstrated that exosomal integrins determine organotropic metastasis: $\alpha6\beta4$ integrin-rich exosomes promote lung metastasis,

while αvβ5 integrins target the liver. This natural tropism can be harnessed therapeutically. Liposomes require **active modifications** (ligand conjugation, antibodies, peptides) to achieve similar specificity. For example, transferrin-conjugated liposomes cross the blood–brain barrier and deliver drugs to gliomas (Ulbrich et al., 2009).

Case Example:

Exosomes engineered with Lamp2b-RVG peptide enabled targeted delivery of siRNA to neurons (Alvarez-Erviti et al., 2011). Liposomes decorated with folate ligands selectively delivered doxorubicin to folate receptor-positive ovarian cancer cells (Gabizon et al., 1999).

Conclusion: Exosomes excel in innate targeting, while liposomes offer **customizable targeting** at the expense of additional design steps.



Figure 2. Distribution of therapeutic applications of nanoparticle systems.

Pie chart illustrating the relative focus of research efforts into therapeutic applications of exosomes and liposomes across major disease areas. Cancer accounts for the largest share (40%), followed by neurological disorders (20%), regenerative medicine (15%), cardiovascular disease (15%), and infectious diseases (10%). The figure highlights the dominance of cancer-focused research in nanomedicine but underscores the growing interest in regenerative and neurological applications.

7.3 Cargo Loading and Release

Exosome cargo is defined by the **parental cell** and microenvironment, though methods such as electroporation, transfection, or chemical conjugation can enhance drug loading (Vader et al., 2016). However, loading efficiency and reproducibility remain challenges.

Liposomes, by contrast, allow predictable **high-efficiency encapsulation** of hydrophilic and hydrophobic drugs. Techniques such as thin-film hydration and ethanol injection are scalable and reproducible (Allen and Cullis, 2013). Controlled release systems (pH-sensitive liposomes) further enhance delivery to tumors.

Case Example:

Exosomes loaded with doxorubicin showed superior uptake by drug-resistant breast cancer cells compared to free drug (Tian et al., 2014).

Liposomal irinotecan (Onivyde®) improved survival in pancreatic cancer by stabilizing drug release and accumulation (Wang-Gillam et al., 2016).

Conclusion: Liposomes outperform in **controlled drug loading**, while exosomes provide biologically relevant, though less standardized, cargo delivery.

7.4 Pharmacokinetics and Half-Life

Exosomes exhibit extended circulation times due to CD47-mediated evasion of mononuclear phagocytes (Morrissey et al., 2020). Yet, biodistribution studies show rapid accumulation in the liver, spleen, and lungs (Wiklander et al., 2015).

Liposomes display pharmacokinetics highly dependent on PEGylation and size. Pegylated liposomes remain in circulation for hours to days, but uptake by the reticuloendothelial system (RES) remains significant (Barenholz, 2012).

Conclusion: Both systems face **RES clearance challenges**, but exosomes may achieve longer retention in certain contexts.

7.5 Manufacturing and Scalability

Exosome production is constrained by:

- Heterogeneity of vesicles.
- Technical challenges in isolation (ultracentrifugation, size-exclusion chromatography, tangential flow filtration).
- Limited yields from cell cultures (Lötvall et al., 2014).
- Liposomes benefit from decades of optimization, with **GMP-scale production and regulatory approval pathways** well established (Allen and Cullis, 2013).

Case Example:

Exosome therapies remain largely preclinical or in early trials.

Liposomal drugs are globally marketed, demonstrating scalability.

Conclusion: Liposomes are currently superior in **industrial feasibility**, though EV-mimetics may close this gap.

7.6 Safety and Regulatory Considerations

Regulatory authorities (FDA, EMA) have approved multiple liposome formulations. Guidelines for **exosome therapeutics** are still emerging, with emphasis on source standardization, purification, and safety testing (Reiner et al., 2017).

Concerns include:

- Potential for horizontal gene transfer via exosomal DNA/RNA.
- Risk of tumor-promoting cargo in certain exosome populations.

Conclusion: Liposomes have a regulatory head start, but exosomes face greater hurdles due to biological complexity.

7.7 Cost and Clinical Feasibility

Exosome-based therapies require cell culture facilities, strict donor screening, and advanced purification technologies. Costs remain high (Lener et al., 2015).

Liposome production is relatively inexpensive and already integrated into pharmaceutical pipelines.

7.8 Overall Comparative Summary

Feature	Exosomes	Liposomes	Other Nanoparticles
Biocompatibility	High (autologous)	Moderate–high (PEGylation helps)	Variable
Immunogenicity	Low (unless allogeneic)	Possible CARPA	Polymer/inorganic toxicity possible
Targeting	Natural tropism	Requires modification	Modifiable
Cargo Loading	Variable, less predictable	High, reproducible	High
Pharmacokinetics	Long, RES clearance	Long (PEGylated)	Variable
Scalability	Low–medium	High	High
Regulatory Approval	Emerging	Multiple FDA approvals	Few (in development)

8. Challenges and Future Perspectives

8.1 Challenges in Exosome-Based Therapeutics

8.1.1 Isolation and Purification

One of the primary barriers to clinical translation of exosome therapeutics is the **difficulty of isolation**. Current methods include:

Differential ultracentrifugation – the most widely used, but time-consuming and yields heterogeneous populations (Théry et al., 2006).

Size-exclusion chromatography (SEC) – preserves exosome integrity but has limited scalability (Böing et al., 2014).

Precipitation-based methods – convenient but risk protein contamination (Helwa et al., 2017).

Tangential flow filtration (TFF) – promising for scale-up but requires optimization (Busatto et al., 2018).

Standardized, GMP-compliant methods are urgently needed to produce homogeneous, reproducible exosome preparations.

8.1.2 Cargo Heterogeneity

Exosome content reflects the **parental cell type and its state**. Tumor-derived exosomes, for example, may carry oncogenic signals. This raises biosafety concerns when using exosomes from certain sources (Kalluri and LeBleu, 2020). Engineering strategies to control exosome cargo are being developed, but reproducibility remains limited.

8.1.3 Biodistribution and Off-Target Effects

Although exosomes exhibit natural tropism, biodistribution studies show that a significant proportion accumulate in the liver, spleen, and lungs (Wiklander et al., 2015). This can dilute therapeutic efficacy and introduce off-target effects. Strategies such as **surface engineering with ligands or peptides** are being investigated to improve targeting precision.

8.1.4 Manufacturing Costs

Large-scale exosome production requires continuous cell culture, expensive reagents, and labor-intensive purification. The cost per therapeutic dose remains prohibitively high compared to synthetic systems (Lener et al., 2015).

8.2 Challenges in Liposome and Synthetic Nanoparticle Therapeutics

8.2.1 Immunogenicity and Toxicity

Liposomes can trigger **complement activation-related pseudoallergy (CARPA)**, leading to hypersensitivity reactions (Szebeni, 2005). Polymeric and inorganic nanoparticles raise additional concerns about long-term accumulation and toxicity (Elsabahy and Wooley, 2012).

8.2.2 Limited Targeting

Without active modification, liposomes distribute passively via the **enhanced permeability and retention (EPR) effect** (Matsumura and Maeda, 1986). However, EPR is highly variable between tumors and patients (Danhier, 2016). This variability limits consistent clinical efficacy.

8.2.3 Scalability vs. Complexity

While liposomes are relatively easy to scale, more advanced designs (stimuli-responsive or ligand-targeted liposomes) introduce complexity in manufacturing and regulatory approval.

8.3 Regulatory Barriers

8.3.1 Exosomes

Currently, there are **no universally accepted regulatory guidelines** for exosome therapeutics. Issues include:

Classification: Are exosomes drugs, biologics, or advanced therapy medicinal products (ATMPs)?

Potency assays: Lack of standardized assays to evaluate therapeutic efficacy.

Batch variability: Differences between exosome batches complicate quality control (Reiner et al., 2017).

8.3.2 Liposomes

Liposomes benefit from established regulatory pathways. However, approval remains complex, requiring detailed data on **lipid composition, stability, biodistribution, and immunogenicity** (Allen and Cullis, 2013).

8.4 Future Directions

8.4.1 Hybrid Systems

Exosome-liposome hybrids combine natural targeting with scalable production. Early studies show that hybrid vesicles can deliver siRNA and chemotherapeutics with enhanced efficiency (Lin et al., 2018).

8.4.2 Synthetic Exosome-Mimetics

Artificial vesicles mimicking exosomal composition are emerging as **next-generation platforms**. Jang et al. (2013) demonstrated exosome-mimetic nanovesicles produced by extrusion, capable of delivering drugs to tumors at scale.

8.4.3 Personalized Medicine

Autologous exosomes derived from a patient's own cells offer a personalized, low-immunogenicity therapeutic option. For instance, tumor-derived exosomes engineered to present antigens could serve as **personalized cancer vaccines** (Zitvogel et al., 1998).

8.4.4 Gene and RNA Therapeutics

Exosomes and lipid nanoparticles have already proven their value in **RNA-based medicine**, highlighted by the success of lipid nanoparticle (LNP)-based mRNA vaccines for COVID-19 (Sahin et al., 2020). Exosomes could serve as next-generation carriers for siRNA, miRNA, and CRISPR-Cas systems (Gilligan and Dwyer, 2017).

8.4.5 Artificial Intelligence in Nanomedicine Design

AI and machine learning are increasingly applied to predict nanoparticle–biological interactions, optimize formulation, and identify therapeutic targets (Costa et al., 2020). This integration could accelerate development and reduce trial-and-error in nanomedicine.

9. **Discussion**

The field of nanomedicine has experienced a rapid evolution in recent years, propelled by advances in molecular biology, material science, and pharmaceutical engineering. Among the most intriguing developments is the study of exosomes and other small particle-based therapeutics, which have emerged as promising vectors for drug delivery, gene therapy, and immunomodulation. Exosomes, naturally occurring extracellular vesicles, are released by virtually all cell types and function as critical mediators of intercellular communication. Their unique biological origin confers remarkable advantages, including innate biocompatibility, low immunogenicity, and the ability to cross biological barriers such as the blood-brain barrier. This intrinsic capacity to shuttle nucleic acids, proteins, and lipids between cells has positioned exosomes as highly versatile therapeutic carriers, capable of modulating cellular phenotypes and influencing complex physiological processes.

Parallel to the exploration of exosomes, synthetic nanocarriers—including liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles—have been extensively developed to deliver therapeutic payloads with precision. These synthetic platforms offer unparalleled control over physicochemical properties, such as particle size, surface charge, and functionalization with targeting ligands. Unlike biological vesicles, synthetic nanocarriers can be engineered to exhibit prolonged circulation time, enhanced stability under physiological conditions, and tunable release kinetics. These characteristics have enabled the translation of several nanoparticle-based therapeutics into clinical applications, exemplifying the potential of these platforms to revolutionize drug delivery and precision medicine.

Comparative analyses of exosomes and synthetic nanocarriers reveal a spectrum of advantages and limitations that must be considered in therapeutic design. Exosomes exhibit inherent targeting capabilities, as their surface proteins often reflect the cellular origin and tissue tropism of the parent cells. This allows exosome-mediated delivery to achieve high specificity, particularly in the context of oncology and regenerative medicine. Furthermore, exosomes are capable of evading phagocytic clearance and bypassing immune surveillance mechanisms more effectively than many synthetic carriers. These properties are largely attributed to the expression of surface markers such as CD47, which confer a “don’t eat me” signal to phagocytes, reducing uptake by the mononuclear phagocyte system.

Despite these advantages, exosomes face several practical challenges. Isolation and purification methods, such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture, often yield heterogeneous populations with variable loading efficiency. Standardization of exosome production remains a critical barrier to clinical translation, as batch-to-batch variability can significantly affect therapeutic outcomes. Moreover, the limited intrinsic cargo capacity of exosomes constrains their ability to deliver large or multiple therapeutic agents. Engineering strategies, such as electroporation, sonication, or chemical modification, have been developed to enhance loading efficiency, yet these approaches can compromise vesicle integrity and bioactivity.

Synthetic nanocarriers, conversely, offer a high degree of reproducibility and scalability, which are essential for regulatory approval and mass production. Liposomes, for instance, have a well-established safety profile and can encapsulate both hydrophilic and hydrophobic molecules, enabling versatile therapeutic applications. Polymeric nanoparticles, constructed from biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), provide controlled release capabilities and can be functionalized with targeting moieties, enhancing tissue specificity. Dendrimers, with their highly branched architecture, offer multivalent surface modification and tunable drug loading, while inorganic nanoparticles, including gold and silica-based platforms, provide unique optical and magnetic properties for theranostic applications. The primary limitation of synthetic systems lies in their potential immunogenicity, off-target accumulation, and limited biological recognition, which can lead to rapid clearance or unintended toxicity. Surface modification strategies, such as PEGylation, have been employed to mitigate these issues, but these modifications can also impact cellular uptake and endosomal escape, creating a complex balance between stability and functional delivery.

The therapeutic application of exosomes extends across diverse medical fields, ranging from oncology to neurodegenerative diseases. Tumor-derived exosomes have been harnessed as natural carriers for chemotherapeutic agents, leveraging their inherent tropism to tumor cells to achieve targeted cytotoxicity while minimizing systemic side effects. In regenerative medicine, mesenchymal stem cell-derived exosomes have demonstrated immunomodulatory and tissue repair properties, promoting angiogenesis, reducing inflammation, and facilitating cellular proliferation in models of cardiac injury, stroke, and musculoskeletal damage. Furthermore, exosomes serve as platforms for nucleic acid delivery, including small interfering RNA (siRNA) and microRNA (miRNA), providing opportunities for gene modulation therapies that are otherwise challenging to achieve due to nucleic acid instability and poor cellular uptake.

Synthetic nanocarriers have similarly been applied across a broad therapeutic spectrum. Liposomal formulations of chemotherapeutics, such as doxorubicin and paclitaxel, have achieved enhanced bioavailability and reduced cardiotoxicity, illustrating the clinical potential of engineered nanoparticles. Polymeric nanoparticles have been leveraged to deliver gene-editing tools such as CRISPR-Cas9 components, enabling precise genome modification in target tissues. The modularity of synthetic carriers facilitates combination therapy, where multiple drugs or therapeutic agents can be co-encapsulated to achieve synergistic effects. In addition, inorganic nanoparticles allow for integration with imaging modalities, enabling real-time tracking of drug distribution, pharmacokinetics, and therapeutic efficacy, thereby supporting the emerging field of theranostics.

A crucial point of comparison between biological and synthetic nanocarriers is the mechanism of cellular internalization and intracellular trafficking. Exosomes utilize receptor-mediated endocytosis, membrane fusion, and phagocytosis to deliver cargo, often exploiting natural signaling pathways for selective uptake. This mechanism not only enhances specificity but also allows for bypassing lysosomal degradation, preserving the functional integrity of delivered biomolecules. Synthetic nanocarriers, on the other hand, primarily rely on endocytic pathways, including clathrin- and caveolin-mediated endocytosis, macropinocytosis, and passive diffusion, which can result in variable intracellular fate and potential degradation of the therapeutic payload. Consequently, strategies to enhance endosomal escape, such as pH-sensitive polymers or membrane-disruptive peptides, have become integral to the design of effective synthetic nanoparticles.

Safety and immunogenicity considerations further differentiate exosomes from synthetic carriers. While exosomes generally exhibit low immunogenicity due to their endogenous origin, there is the potential for pro-tumorigenic or pro-inflammatory effects depending on the cellular source. Tumor-derived exosomes, for example, may carry oncogenic proteins or nucleic acids that could inadvertently promote metastasis if not carefully characterized. Synthetic nanoparticles are more prone to eliciting immune responses, including complement activation, cytokine release, and hypersensitivity reactions. Surface modifications and careful selection of materials are essential to minimize these risks, yet the long-term immunological consequences of repeated administration remain an area of active investigation.

Emerging strategies seek to integrate the advantages of both biological and synthetic systems, giving rise to hybrid nanocarriers. These hybrid platforms combine the biocompatibility and targeting capabilities of exosomes with the structural tunability and

payload versatility of synthetic nanoparticles. Techniques such as exosome-mimetic vesicles, where cellular membranes are fused with synthetic cores, have demonstrated enhanced drug loading and controlled release while retaining natural targeting properties. Similarly, functionalization of exosomes with polymeric or lipid coatings can improve stability, extend circulation time, and facilitate precise therapeutic delivery. These hybrid approaches represent a promising convergence of natural and engineered strategies, aiming to overcome the limitations inherent to each individual system.

Analytical and characterization methods have played a pivotal role in advancing the understanding and application of exosomes and synthetic nanocarriers. Techniques such as nanoparticle tracking analysis, dynamic light scattering, electron microscopy, and mass spectrometry enable detailed evaluation of particle size, surface properties, cargo content, and purity. In addition, advanced omics technologies, including proteomics and transcriptomics, allow for comprehensive profiling of exosomal cargo and functional assessment of therapeutic potential. For synthetic nanoparticles, high-resolution imaging, surface plasmon resonance, and nuclear magnetic resonance spectroscopy provide insights into structural integrity, ligand binding, and physicochemical stability. Standardization of these characterization protocols is essential for reproducibility, regulatory compliance, and successful translation into clinical practice.

The clinical translation of exosomes and synthetic nanocarriers continues to advance, with several promising candidates entering early-phase trials. Exosome-based therapeutics have been investigated in cancer immunotherapy, neurological disorders, and cardiovascular diseases, demonstrating preliminary efficacy and favorable safety profiles. Synthetic nanocarriers have already achieved significant clinical success, particularly in oncology and infectious disease, with approved liposomal formulations and mRNA vaccine platforms serving as transformative examples. Despite these achievements, challenges persist, including the need for scalable production, rigorous quality control, and comprehensive evaluation of biodistribution and pharmacokinetics. Integration of personalized medicine approaches, where nanocarrier design is tailored to individual patient profiles and disease characteristics, may further enhance therapeutic outcomes and minimize adverse effects.

Future perspectives in the field are increasingly focused on precision engineering, multifunctional therapeutics, and regulatory harmonization. For exosomes, the development of cell-free production systems, engineered parental cells, and high-throughput loading techniques are poised to improve scalability and consistency. Synthetic nanocarriers continue to evolve toward stimuli-responsive systems, targeted delivery through receptor-mediated ligands, and co-delivery platforms that integrate therapeutic and diagnostic functions. Interdisciplinary collaboration between material scientists, biologists, pharmacologists, and clinicians will be essential to address the complex challenges associated with clinical implementation and regulatory approval. Additionally, computational modeling and artificial intelligence are expected to play a central role in optimizing design parameters, predicting biodistribution, and anticipating immunological responses, thereby accelerating the translation of both biological and synthetic nanocarriers from bench to bedside.

The comparative evaluation of exosomes and synthetic nanocarriers underscores the complementary nature of these platforms in therapeutic delivery. Exosomes offer unparalleled

biological compatibility, intrinsic targeting, and the potential for modulation of complex physiological processes, while synthetic nanocarriers provide structural tunability, reproducibility, and multifunctional capabilities that facilitate precise therapeutic intervention. The ongoing convergence of these strategies into hybrid systems holds great promise for overcoming existing limitations and expanding the scope of nanomedicine. By integrating advances in molecular engineering, material science, and computational modeling, the next generation of therapeutics is likely to harness the synergistic potential of biological and synthetic nanocarriers, ultimately advancing precision medicine and improving patient outcomes across a spectrum of diseases. Continued research, rigorous standardization, and interdisciplinary collaboration remain pivotal to unlocking the full potential of these innovative delivery systems, establishing a foundation for transformative advances in healthcare and therapeutic innovation.

The dynamic interplay between exosomes and synthetic nanocarriers reflects the broader evolution of nanomedicine, where the focus has shifted from simple drug delivery vehicles to highly sophisticated, multifunctional therapeutic systems capable of modulating cellular environments with precision. Exosomes, as naturally secreted extracellular vesicles, inherently reflect the biological state of their parent cells, carrying complex molecular cargo that includes proteins, lipids, RNAs, and metabolites. This cargo is not merely passive; it actively participates in intercellular communication, influencing gene expression, cellular metabolism, immune responses, and even the tumor microenvironment. The therapeutic potential of exosomes, therefore, lies not only in their ability to transport exogenous drugs but also in their intrinsic bioactivity, which can synergize with delivered therapeutics to amplify therapeutic effects.

A critical aspect of exosome biology is their heterogeneity, which can be both a challenge and an opportunity. Exosomes vary in size, surface marker composition, and cargo content depending on the cell of origin, the physiological or pathological state of the donor cell, and environmental factors. This heterogeneity can influence biodistribution, cellular uptake, and therapeutic efficacy. For example, mesenchymal stem cell-derived exosomes exhibit immunomodulatory and regenerative properties that make them suitable for cardiovascular repair or inflammatory disorders, whereas tumor-derived exosomes often carry oncogenic molecules that can promote metastasis and immune evasion. Understanding and harnessing this heterogeneity is central to the design of targeted therapies. Approaches such as selective enrichment, surface functionalization, and cargo engineering are increasingly used to create exosome populations tailored for specific therapeutic purposes, thereby transforming natural variability into a controllable feature.

Synthetic nanocarriers, in contrast, offer precise control over physicochemical characteristics, enabling customization of particle size, surface charge, hydrophobicity, and functionalization with ligands or antibodies. This tunability allows synthetic systems to be adapted to specific therapeutic contexts. For instance, liposomes with neutral or slightly negative charges can achieve extended circulation time by reducing opsonization, while positively charged polymeric nanoparticles can enhance endosomal escape and intracellular delivery of nucleic acids. Dendrimers and other branched polymeric structures provide multivalent surface presentation, facilitating targeted binding to receptors overexpressed on diseased cells, and enabling co-delivery of multiple therapeutic agents. The precise engineering

of these synthetic systems facilitates reproducibility, scalability, and regulatory compliance, making them well-suited for clinical translation, even if they lack the inherent bioactivity of natural exosomes.

The mechanisms of uptake and intracellular trafficking differ markedly between exosomes and synthetic nanocarriers, with implications for efficacy and safety. Exosomes primarily exploit receptor-mediated endocytosis and direct membrane fusion, allowing for targeted delivery and evasion of lysosomal degradation. This capability is particularly important when delivering labile biomolecules such as RNAs or proteins, which are susceptible to enzymatic degradation in the endolysosomal pathway. Synthetic nanoparticles, while capable of receptor-mediated internalization, often face challenges in endosomal escape, necessitating the incorporation of pH-sensitive polymers, membrane-disruptive peptides, or other endosomolytic strategies to ensure the functional delivery of cargo. The differential trafficking pathways also influence pharmacokinetics and biodistribution; exosomes may preferentially accumulate in tissues reflective of their parental cell tropism, whereas synthetic particles can be engineered to target specific organs, albeit with the risk of off-target accumulation and systemic clearance by the mononuclear phagocyte system.

Immunogenicity remains a central consideration in therapeutic design. Exosomes generally demonstrate low immunogenicity due to their endogenous origin, yet the immunological profile is highly dependent on the donor cell type and the presence of immunomodulatory or pro-inflammatory cargo. Tumor-derived exosomes, for instance, can suppress antitumor immune responses, whereas immune cell-derived exosomes may enhance immune activation and antigen presentation. Synthetic nanoparticles, conversely, often provoke immune recognition, including complement activation and cytokine release, which can limit circulation time and therapeutic efficacy. Surface modifications such as PEGylation and stealth coatings can mitigate these effects, yet these modifications may also hinder cellular uptake or interfere with receptor-mediated targeting, highlighting a delicate balance in synthetic nanocarrier design.

Therapeutic applications of exosomes extend beyond traditional drug delivery, encompassing gene therapy, immunotherapy, and regenerative medicine. Exosomes can carry small interfering RNAs (siRNAs), microRNAs, messenger RNAs, and even CRISPR-Cas components, enabling modulation of gene expression in target cells. For instance, exosomes loaded with tumor-suppressive miRNAs have demonstrated the capacity to inhibit oncogenic pathways in preclinical cancer models, while exosomes carrying neuroprotective RNAs have shown promise in mitigating neuronal injury and neurodegeneration. In regenerative medicine, exosomes derived from stem cells promote angiogenesis, modulate inflammatory responses, and facilitate tissue repair, highlighting their dual role as both carriers and active therapeutic agents. The ability to combine exogenous cargo with intrinsic bioactivity positions exosomes as a uniquely versatile platform capable of addressing multifactorial disease mechanisms.

Synthetic nanocarriers, while lacking endogenous bioactivity, excel in versatility and multifunctionality. Liposomes, for example, can encapsulate hydrophilic drugs in their aqueous core and hydrophobic drugs within the lipid bilayer, providing broad compatibility with diverse therapeutic molecules. Polymeric nanoparticles offer controlled release profiles, essential for maintaining therapeutic concentrations over extended periods, while dendrimers and micelles

enable co-delivery of synergistic drug combinations. Inorganic nanoparticles introduce additional functionalities, such as imaging contrast, photothermal properties, or magnetic guidance, creating opportunities for integrated theranostic applications. This multifunctionality has enabled synthetic nanocarriers to become a cornerstone of contemporary drug delivery, exemplified by the rapid development and deployment of mRNA vaccines for infectious diseases, which rely on lipid nanoparticles to protect and deliver genetic cargo with high efficiency.

Hybrid systems that combine the strengths of exosomes and synthetic nanoparticles represent a rapidly emerging frontier. Exosome-mimetic vesicles, where natural membranes are fused with synthetic cores, offer enhanced loading capacity while preserving the targeting and biocompatibility of native exosomes. Such systems allow for the co-delivery of multiple payloads, precise control over release kinetics, and the integration of imaging or diagnostic functionalities. Surface engineering of exosomes with polymers or ligands further extends their functional versatility, enabling prolonged circulation, targeted delivery, and controlled release, while retaining the biological recognition features intrinsic to exosomes. These hybrid approaches exemplify the convergence of biology and engineering in the pursuit of optimized nanotherapeutics.

Analytical and characterization methods are essential for understanding the properties, behavior, and therapeutic potential of both exosomes and synthetic nanocarriers. Techniques such as nanoparticle tracking analysis, dynamic light scattering, flow cytometry, and electron microscopy allow for detailed assessment of size distribution, surface morphology, and concentration. High-resolution omics approaches, including proteomics, lipidomics, and transcriptomics, provide comprehensive profiling of exosomal cargo, enabling identification of functional molecules and optimization of therapeutic design. For synthetic nanoparticles, physicochemical characterization through zeta potential measurement, nuclear magnetic resonance, spectroscopy, and imaging informs stability, surface chemistry, and interaction with biological systems. Standardization of these methods is crucial to ensure reproducibility, regulatory compliance, and successful clinical translation.

The translational landscape for exosome- and nanoparticle-based therapeutics continues to expand, with clinical trials exploring a wide range of indications. Exosomes have been investigated for their potential in cancer immunotherapy, neurological disorders, cardiovascular repair, and autoimmune diseases, demonstrating promising preliminary safety and efficacy profiles. Synthetic nanoparticles have achieved significant clinical success, particularly in oncology and infectious disease, with approved liposomal chemotherapeutics, polymeric nanoparticle-based formulations, and lipid nanoparticle-based mRNA vaccines illustrating their transformative impact. Despite these advances, challenges remain, including scalable production, batch-to-batch consistency, regulatory oversight, and comprehensive assessment of biodistribution, pharmacokinetics, and long-term safety. Personalized nanomedicine approaches, where therapeutic platforms are tailored to individual patient profiles and disease characteristics, are likely to enhance efficacy and minimize adverse effects, representing the next frontier in clinical translation.

Mechanistic insights into cellular uptake, intracellular trafficking, and payload release are critical for optimizing both exosomal and synthetic nanocarrier therapeutics. Exosomes

exploit natural ligand-receptor interactions to achieve selective uptake, often circumventing lysosomal degradation and enabling efficient cytoplasmic delivery of cargo. Synthetic nanoparticles require careful design to mimic these advantages, utilizing strategies such as endosomolytic polymers, pH-responsive coatings, and receptor-targeted ligands to improve intracellular delivery. Understanding the intracellular fate of delivered therapeutics, including subcellular localization, metabolic processing, and exocytosis, is essential for predicting therapeutic efficacy and minimizing off-target effects. The integration of live-cell imaging, single-particle tracking, and computational modeling provides valuable tools for elucidating these mechanisms and guiding rational design.

Safety, immunogenicity, and biocompatibility remain central considerations for therapeutic development. Exosomes, derived from autologous cells, generally exhibit minimal immune activation, yet their bioactive cargo can elicit unintended effects if derived from pathological or immunogenic sources. Tumor-derived exosomes may carry oncogenic molecules, while immune cell-derived exosomes may trigger exaggerated immune responses. Synthetic nanoparticles, particularly those with non-biodegradable components, face potential toxicity, complement activation, and systemic accumulation. Strategies such as surface functionalization, biodegradable polymer selection, and incorporation of endogenous biomimetic components are increasingly used to mitigate these risks, yet long-term safety data remain limited. Comprehensive preclinical studies, coupled with standardized regulatory frameworks, are essential for the responsible translation of both exosomal and synthetic therapeutics.

The integration of computational modeling, artificial intelligence, and high-throughput screening is reshaping the development of nanotherapeutics. Predictive models of biodistribution, immune response, and therapeutic efficacy enable the rational design of exosomes and synthetic nanocarriers, reducing empirical experimentation and accelerating optimization. Machine learning algorithms can identify patterns in exosomal cargo composition, predict target tissue tropism, and guide engineering strategies to enhance specificity and functional delivery. For synthetic nanoparticles, computational tools facilitate the design of surface ligands, optimize physicochemical properties, and predict interactions with biological systems. This convergence of data-driven approaches with experimental validation is driving a new paradigm in nanomedicine, where therapeutics are precisely tailored to disease mechanisms and patient-specific contexts.

Future directions in the field emphasize multifunctional, modular, and personalized approaches. Exosomes are being engineered to carry therapeutic payloads, imaging agents, and targeting ligands simultaneously, enabling integrated diagnosis and therapy. Synthetic nanoparticles continue to evolve toward stimuli-responsive systems that release cargo in response to pH, temperature, enzymatic activity, or external triggers such as light or magnetic fields. The combination of biological and synthetic elements in hybrid nanocarriers represents a strategic approach to maximize therapeutic efficacy, minimize toxicity, and achieve precise spatiotemporal control over delivery. Regulatory harmonization, scalable manufacturing, and quality assurance remain critical challenges, requiring collaboration across academic, industrial, and regulatory sectors to ensure safe and effective clinical translation.

The exosomes and synthetic nanocarriers each offer unique advantages and face distinct limitations, underscoring the complementary nature of these platforms. Exosomes provide inherent targeting, biocompatibility, and bioactivity, while synthetic nanocarriers offer tunable physicochemical properties, multifunctionality, and reproducibility. The development of hybrid systems, advanced engineering techniques, and personalized nanomedicine approaches holds significant promise for overcoming existing challenges and expanding the therapeutic potential of these platforms. Continued research into mechanistic insights, scalable production methods, safety assessment, and clinical translation is essential to fully realize the transformative potential of exosome- and nanoparticle-based therapeutics. By integrating biological principles with engineering innovation, the next generation of nanomedicine is poised to revolutionize disease treatment, improve patient outcomes, and establish a new standard for precision, safe, and effective therapeutic delivery.

10. Conclusion

Exosomes and synthetic nanoparticles such as liposomes represent **two complementary paradigms** in therapeutic delivery. Exosomes, with their natural origin, biocompatibility, and targeting capabilities, are poised to revolutionize personalized medicine but face hurdles in scalability and standardization. Liposomes, by contrast, have decades of clinical validation, offering predictable and reproducible platforms, yet lack the biological sophistication of exosomes.

The future likely lies in **hybrid strategies**: exosome-inspired synthetic vesicles, exosome-liposome chimeras, and personalized exosome therapies integrated with synthetic nanocarriers. Overcoming manufacturing, regulatory, and safety challenges will be essential for both systems to achieve widespread clinical adoption.

References

- Adler-Moore, J., & Proffitt, R. T. (2002). Amphotericin B lipid preparations: what are the differences? *Clinical Microbiology and Infection, 8*(Suppl 4), 27–34.
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews, 65*(1), 36–48.
- Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nature Biotechnology, 29*(4), 341–345.
- Atkin-Smith, G. K., & Poon, I. K. (2017). Disassembly of the dying: mechanisms and functions. *Trends in Cell Biology, 27*(2), 151–162.
- Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. *Journal of Molecular Biology, 13*(1), 238–252.
- Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release, 160*(2), 117–134.

- Böing, A. N., van der Pol, E., Grootemaat, A. E., Coumans, F. A., Sturk, A., & Nieuwland, R. (2014). Single-step isolation of extracellular vesicles by size-exclusion chromatography. *Journal of Extracellular Vesicles, 3*(1), 23430.
- Busatto, S., Vilanilam, G., Ticer, T., Lin, W. L., Dickson, D. W., Shapiro, S., ... & Tang, Q. (2018). Tangential flow filtration for highly efficient concentration of extracellular vesicles. *Biochemical and Biophysical Research Communications, 493*(1), 25–31.
- Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., ... & Guo, W. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature, 560*(7718), 382–386.
- Cocucci, E., & Meldolesi, J. (2015). Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends in Cell Biology, 25*(6), 364–372.
- Colombo, M., Raposo, G., & Théry, C. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annual Review of Cell and Developmental Biology, 30*, 255–289.
- Costa, P. M., Cardoso, A. L., Mendonça, L. S., Serani, A., Custódio, J. B., & Moreira, J. N. (2020). The emerging role of artificial intelligence in nanomedicine. *Advanced Drug Delivery Reviews, 159*, 306–317.
- Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., ... & Guo, Z. (2008). Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. *Molecular Therapy, 16*(4), 782–790.
- Danhier, F. (2016). To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? *Journal of Controlled Release, 244*, 108–121.
- Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release, 161*(2), 505–522.
- Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., & Vekrellis, K. (2010). Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. *Journal of Neuroscience, 30*(20), 6838–6851.
- Elsabahy, M., & Wooley, K. L. (2012). Design of polymeric nanoparticles for biomedical delivery applications. *Chemical Society Reviews, 41*(7), 2545–2561.
- Gabizon, A., Shmeeda, H., & Barenholz, Y. (1999). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. *Clinical Pharmacokinetics, 42*(5), 419–436.
- Gan, L. M., Lagerström-Fermér, M., Carlsson, L. G., Arfvidsson, C., Egnell, A. C., Rudvik, A., ... & Sylvén, C. (2021). Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. *Nature Communications, 12*(1), 871.

- Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., & Richette, P. (2012). Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. *Expert Opinion on Drug Delivery, 9*(11), 1319–1323.
- Gillies, E. R., & Fréchet, J. M. (2005). Dendrimers and dendritic polymers in drug delivery. *Drug Discovery Today, 10*(1), 35–43.
- Gilligan, K. E., & Dwyer, R. M. (2017). Engineering exosomes for cancer therapy. *International Journal of Molecular Sciences, 18*(6), 1122.
- Gupta, A. K., & Gupta, M. (2005). Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials, 26*(18), 3995–4021.
- György, B., Szabó, T. G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., ... & Buzás, E. I. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles in immune modulation and therapy. *Cellular and Molecular Life Sciences, 68*(16), 2667–2688.
- Helwa, I., Cai, J., Drewry, M. D., Zimmerman, A., Dinkins, M. B., Khaled, M. L., ... & Liu, Y. (2017). A comparative study of serum exosome isolation using differential ultracentrifugation and three commercial reagents. *PLOS ONE, 12*(1), e0170628.
- Holst, J., Martin, D., Arnold, R., Huergo, C. C., Oster, P., O'Hallahan, J., & Rosenqvist, E. (2009). Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. *Vaccine, 27*(Suppl 2), B3–B12.
- Hoshino, A., Costa-Silva, B., Shen, T. L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., ... & Lyden, D. (2015). Tumour exosome integrins determine organotropic metastasis. *Nature, 527*(7578), 329–335.